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Abstract
Spinal cord injury results in significant mortality and morbidity, lifestyle changes, and difficult 
rehabilitation. Treatment of spinal cord injury is challenging because the spinal cord is both 
complex to treat acutely and difficult to regenerate. Nanomaterials can be used to provide effective 
treatments; their unique properties can facilitate drug delivery to the injury site, enact as 
neuroprotective agents, or provide platforms to stimulate regrowth of damaged tissues. We review 
recent uses of nanomaterials including nanowires, micelles, nanoparticles, liposomes, and carbon-
based nanomaterials for neuroprotection in the acute phase. We also review the design and neural 
regenerative application of electrospun scaffolds, conduits, and self-assembling peptide scaffolds.
1. Spinal Cord Injury: Current Outlook
Spinal cord injury (SCI) is a widespread problem affecting about 250,000 people living in 
the United States, with an estimated 13,400 new cases each year.1 SCI tragically often 
affects the youngest and most active segment of our society, with 60% of injuries occurring 
in those under the age of 30. The most common cause, making up greater than 40% of SCI, 
is motor vehicle accidents. Other common causes include recreation-related accidents, work-
related accidents, falls, and acts of violence.2 The pathological progression of SCI is often 
separated into two categories: primary injury and secondary injury.
Primary injury involves initial trauma and local tissue injury caused by bone fracture and 
stretching, flexion, rotation, laceration, compression, or displacement of the spinal cord3. 
Initial injury after a contusive SCI mainly damages the grey matter of the spinal cord, 
resulting in hemorrhage and disruption of the blood flow.
The secondary injury denotes the spread of damage from the original site to adjacent tissue 
through a cascade of deleterious reactions to the trauma.4 The extent of secondary injury is 
proportional in magnitude to the primary injury. Secondary injury includes many different 
mechanisms, including three key pathophysiological events. First, damage to blood vessels 
is especially prevalent in small vessels and results in ischemia, thrombosis, and hypoxia; 
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starving the tissue of nutrients. Second, reactive oxygen species are produced during 
ischemia and contribute to oxidative stress. Once the ability of cells to protect themselves 
from oxidative stress with antioxidants has been exceeded, the oxidation of proteins, nucleic 
acids, and lipids will occur and perpetuate the damage. Third, membrane disruption and 
depolarization of the cells from primary damage causes voltage dependent channels in the 
cells to open, resulting in a mass release of ions, edema, and intracellular Ca2+ overload. 
Calcium overload contributes to damage by inhibiting cellular respiration and stimulating 
calcium dependent lipases and proteases, which subsequently degrade important protein 
structures in the central nervous system (CNS). This chain of events eventually results in 
recruitment of immune cells, apoptosis, disruption of synaptic connections, and also axonal 
degradation, contraction, and demyelination.3, 5-7
The progression of primary injury and secondary injury is highlighted in Figure 1 adopted 
from GhoshMitra et al.7 In the chronic phase, damaged tissue is cleared away by microglia 
and macrophages, leaving a fluid-filled cavity and an astrocyte-populated glial scar. 
Molecules that inhibit axon growth are expressed, and the glial scar and cyst remain as 
barriers to reconnection.3, 8, 9
Victims who survive SCI can expect to live long lives, but they face extensive rehabilitation 
and long-term disability. Rehabilitation prospects depend on the severity of the damage. 
Individuals with injury at or below T-6, may be candidates for walking.10 These patients are 
re-taught how to balance and learn a modified “swing-to” gait. Braces or crutches may be 
used to walk and energy expenditures are much higher, 800%, for this gait as compared to a 
normal stride.10
Currently, the drug used clinically to acutely treat SCI is an extremely large dose (30mg/kg 
I.V. for the first hour, 5.4mg/kg/hr drip for 24 hours) of methylprednisolone (MP) 
administered within the first 8 hours post-injury.11 MP is a glucocorticoid, and is thought to 
work through several mechanisms, including inhibition of lipid peroxidation and 
suppression of inflammation by reducing cytokine release and expression.12 The efficacy of 
MP treatment is highly controversial.13, 14 The dose prescribed in the case of SCI is the 
highest dose of any steroid in a 24 - 48 hour period11 and is associated with serious side 
effects.15, 16 Moreover, MP is only effective if given in the first 8 hours post-injury, after 
which MP treatment may do more harm than good.17 Indeed, it is debated whether the small 
improvements are worth risking many serious side effects which may include myopathy, 
infections, and gastric bleeding.13
The inefficacy of MP treatment is partly associated with the special environment of the CNS 
and the spatio-temporal profile of SCI. The CNS has a limited capacity for regeneration due 
to inhibitory factors.18 Additionally, the blood spinal cord barrier (BSCB) protects and 
regulates the parenchyma and provides a specialized microenvironment for the cellular 
constituents of the spinal cord. This functional equivalent of the blood brain barrier provides 
special challenges of its own; endothelial cells that line the capillaries form tight junctions 
that keep most drugs from entering the parenchyma.19 In order for drugs like MP to reach 
therapeutic levels at the injury site, an extremely high systemic dose is required. These high 
doses are undesirable, as they can result in toxicity and systemic side effects.20 Systemic 
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delivery also faces challenges from renal clearance of drug, limited drug circulation time, 
and drug degradation.21 To combat these shortcomings, local delivery methods like bolus 
injection into the intrathecal space and osmotic minipumps have been endeavored. 
Clearance of the cerebrospinal fluid into the lymph and venous system, cellular barriers, and 
diffusional barriers limit these local delivery methods to some extent. These methods may 
also disrupt the tissue and prevent recovery of the BSCB after injury.22, 23 Osmotic 
minipumps face additional challenges with blockage and infection, and the pumps have not 
been widely accepted.24 An additional problem confronting SCI treatment stems from the 
limited treatment time window. Secondary injury progresses rapidly after initial trauma and 
continues for days or months 25. Subsequent damage is difficult to overcome,8 as after 
secondary injury has occurred the local environment is not conducive to regeneration. 
Inhibitory factors are produced that keep neurons from growing, and the lesion and glial 
scarring create a physical barrier that blocks reconnection. Subsequently, early intervention 
is very important.
Research for treating SCI can be broadly divided into two main areas: neuroprotection and 
regeneration. Neuroprotection focuses on preventing the spread of secondary injury, 
reducing the subsequent damage. Because secondary injury involves many different injury 
mechanisms, many different neuroprotective drugs or therapies may be applied to mitigate 
the damage. Neuroprotective agents can prevent the spread of secondary injury through 
many different methods, which can include reducing edema, relieving inflammation, 
reducing excitotoxicity, preventing apoptosis and necrosis, scavenging free radicals, 
repairing damaged membranes, or restoring the ionic balance.5, 26, 27 Some neuroprotective 
therapies that have been tested include delivery of antibodies against a cell adhesion 
molecule present on immune cells 28; erythropoietin 29, 30; minocycline 31, 32 an antibiotic 
used for its ability to enter the CNS; and steroids like MP12, 33. The efficacy of these 
methods has been limited so far. Neuroprotective treatments must contend with the 
challenging spinal cord environment. Because of the BSCB, neuroprotective therapy faces 
difficulties delivering therapeutic agents effectively.
Regenerative therapy focuses on regaining neural circuitry and functionality in the damaged 
tissue. Regeneration must overcome both intrinsic (e.g., lack of intrinsic capacity to 
regenerate) and extrinsic (e.g., glial scarring and production of inhibitory factors) 
environmental challenges.34 Although natural regeneration is difficult, many different 
methods for regenerating the injured spinal cord have been investigated. Three main areas of 
research include neural implantation, electrical stimulation, and environmental 
modification.35 Although there has been some success in recovering spinal cord functions 
through these methods,36-41 problems still persist in directing axonal growth and reknitting 
tissue to support functional conduction. To summarize, the challenging pathophysiology of 
SCI has prevented development of effective clinical treatment. The advent of nanomedicine 
may provide new tools for tackling this problem.
2. Nanomedicine: New Hope for Overcoming Barriers to Treatment
Nanomaterials have unique benefits that can be applied to solve the multifaceted and 
challenges facing neuroprotective and regenerative therapies. Nanomaterials can be used as 
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carriers which provide particular advantages for neuroprotection. First, nanocarriers have the 
potential to increase the bioavailability of neuroprotective drugs through targeted delivery 
and extended circulation times.42 Second, because of their size, nanocarriers have the 
potential to cross barriers like the BSCB and cell membrane walls.43 Furthermore, the large 
surface area to mass ratio of nanocarriers allows for compounds, such as targeting moieties 
or drugs, to be bound to the surface. Some kinds of nanocarriers may have other desirable 
benefits on their own, such as the ability to self-assemble, scavenge reactive oxygen species, 
or act as imaging probes.44
Nanomaterials can also aid regeneration. The goal of neural-regeneration is to reestablish 
conduction in damaged spinal cords by promoting axonal re-growth. A growth permissive 
environment can be provided by blocking inhibitory factors, promoting neurotrophic factors, 
aligning axons, or circumventing glial scarring.45-49 Scaffolds composed of nanomaterials 
can mimic the natural cell environment and influence cellular growth, differentiation, and 
proliferation.50 These nanomaterial scaffolds can be easily functionalized with molecules 
that support attachment or axonal growth, and thus provide a substrate that promotes and 
guides new tissue growth.
Although nanomedicine for treating spinal cord injury is a young field, great progress has 
already been made in both neuroprotection and regeneration areas, as highlighted in the 
following sections.
3. Nanomaterials for Neuroprotection
Nanomaterials can be used as a carrier for various pharmaceutical agents by providing 
targeting capability, greater delivery efficiency, or protection of drug from degradation. 
Nanomaterials can also be used as for neuroprotective treatment, performing functions such 
as scavenging free radicals, or patching the cell membranes. The main applications to date 
have been focused on membrane integrity, immune response, and oxidative stress. 
Specifically, nanowires, nanoparticles (NPs), micelles, liposomes, and carbon-based 
nanostructures have all been investigated for their respective neuroprotective or drug 
delivery capabilities. Table 1 summarizes the neuroprotective treatments to date. Details are 
discussed in the following subsections.
3.1 TiO2 nanowires
Nanowires have been applied in SCI treatment with limited success. In recent years 
nanowires have been explored for application in sensors, electronics, and optics due to their 
unique properties51, 52. Compared to other nanostructures, nanowires have not been as 
widely investigated for applications in drug delivery, although there have been several 
recent studies.53, 54 Even though the mechanism is unknown, nanowires have been 
postulated to improve the bioavailability of neuroprotective compounds to which they are 
conjugated.55 Sharma et al tested this hypothesis, and found that innocuous TiO2 nanowires 
were able to improve the efficacy of neuroprotective Acure compounds to which they are 
attached.56, 57 In an in vivo right dorsal horn incision rat model of SCI, the nanowired 
compounds were locally applied to the injury site at 5 minutes and 60 minutes post-injury. 
Functional recovery, BSCB permeability, edema, and pathology were tested at 5 hours post-
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injury. The nanowired compounds performed significantly better than the un-wired 
compound and no-treatment controls, although the benefits were greatly reduced with 
delayed application. While timeliness is important for treating SCI, it is important that the 
drug is effective within a clinically relevant time frame, as patients are unlikely to get 
instantaneous treatment for their injury. Furthermore, as secondary injury continues to 
progress for several days or weeks post-injury,25 the use of such a short evaluation time 
frame is questionable as the injury is incomplete at the time of evaluation. The authors 
clarify that the incision model was chosen for injury consistency and for monitoring the 
spread of secondary injury, although the model is not as clinically relevant as other injury 
models.58 While the improved efficacy of the wired compounds is demonstrated, the 
diminished capabilities with delayed application, the short evaluation time frame (5 hours), 
and the model of SCI need to be considered when evaluating this treatment for practical 
usage.
3.2 Micelles
Micelles have been used for many years to deliver drugs, and have found applications in 
drug delivery to the spinal cord.59, 60 Micelles are formed from self-assembling amphiphilic 
molecules, consisting of a hydrophobic core and a hydrophilic shell. Hydrophobic drug can 
be encapsulated in the core, which protects it from degradation and improves the drug's 
circulation half-life.61 Due to their size and flexibility, micelles are resistant to glomerular 
filtration, which extends their retention time in blood.42 Micelles are also easily adapted; 
their size, chemical composition, and surface modifications can be altered to suit a specific 
application. This allows for micelles to hold various drugs and markers, such as imaging 
agents. Poly(ethylene glycol) (PEG) is commonly used as the hydrophilic moiety of micelles 
due to its solubility, ability to extend circulating time, efficacy as a steric protector, and 
ability to prevent opsonization and clearance by macrophages.62-64 The micelle surface can 
also be modified to permit crossing of the BSCB.65
There have been several reports of micelles for SCI treatment. Chen et al improved the 
bioavailability of MP in the spinal cord using Poly(ethylene oxide)-poly(propylene oxide)-
poly(ethylene oxide) (PEO-PPO-PEO, Pluronic) polymeric micelles as a delivery vehicle59. 
Like PEG, Pluronic is a popular component of drug delivery systems and has been shown to 
cross the blood-brain barrier. Furthermore, it has been shown to be temperature-responsive 
and forms micelles at body temperature. Using in vivo rabbit and mice models, release 
characteristics and bioavailability of MP were tested, and mRNA and protein levels of Bcl-
xl anti-apoptotic protein were monitored. The micelle increased the bioavailability of MP in 
the spinal cord to levels 2 - 3 times higher than that with standard systemic delivery, and the 
plasma half-life was increased 7 times. At 7 hours post-injury, the mRNA and protein levels 
of Bcl-xl were also significantly increased over controls. Although in this particular study it 
is not clear whether this increase in bioavailability was due to improved crossing of the 
BSCB or merely improved circulation time, the micelles were able to significantly improve 
bioavailability to the spinal cord.
Shi et. al in vivo explored polymeric micelles as a direct means of treating SCI.60 In 
extensive in vivo and ex vivo testing, monomethoxy PEG-poly(D,L-lactic acid) 
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(mPEGPDLLA) di-block copolymer micelles were evaluated. Figure 2 highlights some 
results of this study. The mPEG-PDLLA micelle's neuroprotective effects stem from the 
amphiphilic polymer components acting to seal the damaged cell membranes. In this study, 
Ca2+ influx, lesion volume, immune-reactivity, ex vivo compound action potential, 
functional recovery, toxicity, and myelin degradation were analyzed to give a complete 
overview of the treatment effects. Presence of the polymer micelles at the injury was 
confirmed with confocal microscopy using FITC-conjugated micelles. Significant 
improvements over both saline-treated and PEG-treated controls were found in all areas 
investigated. Notably, the compound action potential, which is a measurement of what 
proportion of axons are conducting action potentials, was significantly restored. After 20 
minutes, without treatment the compound action potential recovered only to about 18.5%, 
whereas with treatment it recovered to about 66.5%. Treatment with mPEG-PDLLA 
micelles was also able to improve functional recovery, measured by the Basso Beattie 
Bresnahan (BBB) locomotor scale. At 4 weeks post–injury treatment animals recovered to 
about 12.5, which was significantly different than both the saline control group (7.1) and the 
30%PEG group (7.0). This difference is noteworthy, considering that a BBB score of 12 
signifies axonal transduction through the lesion site.66 These results are striking, especially 
since no drug was delivered in this experiment and there was no apparent toxicity. Although 
recovery was not complete, this treatment could be expanded upon, for example, by 
encapsulation or conjugation of a drug, to possibly achieve even greater results. This study 
demonstrates a unique, simplistic, and effective use of micelles in treating SCI.
While micelles are useful carriers, they do have limitations. Micelles can be unstable in the 
blood and can dump their drug payload soon after injection. Studies performed using Förster 
resonant energy transfer between hydrophobic fluorescent probes entrapped in the core of 
polymeric micelles show that the hydrophobic probes in the core are quickly released from 
the micelles.67 Förster resonant energy transfer efficiency was significantly reduced within 
15 minutes of injection, indicating that the micelles were becoming dissociated and were 
losing their payload. This instability stems from interactions of the micelle with blood 
lipoproteins, α- and β-globulins.68 To combat this type of dissociation during circulation, 
stable cross-linked micelles have been developed for cancer treatment.69 Similar cross-
linking strategies could be employed in the development of nanocarriers for treating spinal 
cord injury.
3.3 Nanoparticles (NPs)
The most extensively tested NPs for drug delivery to the spinal cord have been polymeric 
NPs and silica NPs, although other NPs are also being investigated. Like micelles, NPs can 
be coated or functionalized with targeting peptides to improve delivery efficacy.65 
Polymeric NPs are typically solid and biodegradable, which allows drugs to be adsorbed, 
entrapped, encapsulated, or chemically linked to the particle through surface modification.70 
In experiments performed by Kim et al poly[lactic-co-glycolide] (PLGA) NPs were loaded 
with MP for local delivery in an in vivo dorsal over hemisection rat model of SCI.71 MP 
loaded NPs (MP-NPs) were compared to equivalent local dose of MP, clinical systemic dose 
of MP, and saline loaded NPs. The MP-NPs were topically applied to the injury site and 
embedded in an agarose gel. In these experiments, expression of secondary injury indicators 
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(Calpain, iNOS, Bcl-2, and Bax3, 5) was quantified at 24 hours post-injury. Functional 
recovery was measured by beam and grid walking tests at 1, 2, and 4 weeks post-injury. 
Lesion volume and cellular reactivity were also assessed. Animals treated with the MP-NPs 
demonstrated reduced immune response, reduced pro-apoptotic protein reactivity, and 
reduced lesion volume. MP-NP treated rats recovered earlier than control rats, but the early 
differences between groups dwindled with time, and at 4 weeks the gridwalking results were 
not significantly different. Beam walking results showed significant differences between all 
groups at all measured times, with MP-NP rats recovering more function. While, as noted by 
the authors, the dorsal over hemisection injury model is not representative of most SCI 
cases, these results showed relationships between functional recovery, protein expression, 
and pathophysiology. These studies also demonstrated some benefit associated with MP-NP 
treatment. Ideally, studies of systemic toxicity would have been performed to give an 
indication of the reduction in toxicity that could be expected with NP treatment, as reducing 
toxicity compared to conventional MP treatment is a significant goal. The use of agarose gel 
and local application in this treatment is worth noting, as hydrogels are extensively 
researched for treating SCI. This local agarose treatment may have additional advantages 
related to sustained and targeted release that are not associated with NP delivery. This 
agarose delivery system does not, however, avoid pitfalls related to local treatment.
A less typical application of polymeric NPs is demonstrated by Chen et al in their extension 
of Pluronic, also used in micelles, in a temperature responsive, magnetic, controlled-dosing 
drug delivery vehicle.72 Pluronic chains, which contain both hydrophobic poly(propylene 
oxide) and hydrophilic poly(ethylene oxide) segments, assemble on modified anionic 
superparamagnetic iron oxide NPs through strong ionic interactions. At low temperatures 
the copolymer chains are fully extended and the polymer shell is open and hydrated, 
allowing for loading of therapeutic agents. At higher temperatures the copolymer dehydrates 
and contracts, inhibiting the diffusion of molecules out of the shell. As the NPs are 
magnetic, they can be directed to their destination through application of an external 
magnetic field.
Monosialotetrahexosylganglioside (GM-1), which is reported to re-establish function of the 
damaged CNS,73, 74 was loaded into the NPs. The loaded NPs were tested in a complete 
transection rat model of SCI. The NPs were applied and sealed with fibrin glue post-injury, 
and their efficacy was evaluated four weeks later using immunohistochemistry methods. No 
behavioral or functional recovery testing was performed, as the focus of this study was 
primarily on synthesis and characterization. Rats treated with GM-1 loaded NPs 
demonstrated significant histological improvement of the spinal cord; many nerve fibers 
regenerated in treated animals, while the no-treatment and unloaded NP control animals 
showed no evidence of regeneration. Although the delivery mechanism for this NP system 
was fascinating albeit complex, the topical means through which they were delivered in this 
study did not demonstrate the full targeting and non-invasive potential of the system. 
Magnetic directing of the NPs was not tested in vivo, nor were the pharmacokinetics 
characterized in vivo.
Silica NPs (SiNPs), which have been demonstrated to be non-toxic in vivo, also have been 
studied in depth for treatment of SCI. Cho et al demonstrated the effectiveness of PEG 
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decorated SiNPs (PSiNPs) in ex vivo and in vivo contusion guinea pig models of SCI.75, 76 
In this case the NPs do not carry drug, but function instead to increase the bioavailability o 
PEG, which has well documented neuroprotective effects77-79 and seals damaged cell 
membranes80, 81. Using NPs the effective concentration of PEG was lowered by 2 orders of 
magnitude as compared to treatment with PEG alone. This is significant, as the use of PEG 
for treatment has been found to be effective, but delivery is limited by the viscosity and by 
the concentration of PEG monomers, which can be toxic at high doses.82, 83 PSiNPs were 
compared to PEG alone, SiNPs alone, a no injury control, and a treatment control. In ex vivo 
transection assays, PSiNPs reduced lactate dehydrogenase loss to control levels, indicating 
restored membrane integrity; reduced reactive oxygen species to control levels; and reduced 
lipid peroxidase production. PEG was also shown to selectively target the damaged areas of 
the cord. In vivo somatosensory evoked potential measurement was used to demonstrate 
conduction through the injury site. In this test, 14 out of 15 animals treated with PSiNPs 
recovered somatosensory evoked potential, whereas no controls showed any somatosensory 
evoked potential recovery by 9 days post-injury. Furthermore, compound action potential 
measurements with marked amplitudes were recovered in all treated animals. The electrical 
recovery in this study is an impressive indication of recovery.
In another study by Cho et al, the efficacy of hydralazine-loaded mesoporous silica NPs 
functionalized with PEG (MSN-hy-PEG) was investigated in an in vitro acroleinchallenged 
neuron cell model.84 Acrolein, a well-known aldehyde, is produced during secondary injury 
as a byproduct of lipid peroxidation and is toxic to spinal tissue.85 Hydralazine combats this 
toxicity by binding acrolein.86 PEG serves several purposes in this design; it reduces free-
radical-mediated injury, seals membranes, and targets damaged regions of the CNS. PEG 
can also be used to control release of hydralazine from the NPs, since the large PEG 
molecules slow the drug's escape. The authors demonstrate that MSN- hy-PEG NPs restore 
cell membrane function and rescue cells challenged with acrolein. Lactate dehydrogenase, 
MTT, ATP, and glutathione assays were used to evaluate membrane integrity, 
mitochondrian function, metabolic state, and oxidative stress, respectively. MSN-hy-PEG 
alleviated acrolein toxicity in all assays, and lactate dehydrogenase release was actually 
lower in the NP treated group than the unchallenged control. This delivery and treatment 
system shows promise in vitro, but animal testing will be necessary for validation.
Several other lesser-known NPs are under early stage investigation for treating SCI because 
of their desirable properties, which include free radical scavenging or capability of crossing 
the BSCB. Past studies have shown that Poly(butyl cyanoacrylate) NPs (PBCANPs) coated 
with the surfactant polysorbate-80 are able to penetrate the blood brain barrier.87-89 Upon 
injection these particles are coated with adsorbed plasma proteins, notably apoplipoprotein 
E, and it is believed that they are mistaken for low-density lipoprotein particles and 
internalized by the low density lipoprotein uptake system, allowing them to cross the blood 
brain barrier.90 In a study by Reukov et al, PBCA-NPs were conjugated with superoxide 
dismutase and anti-glutamate N-methyl D-aspartate receptor 1 (NR1) antibody in order to 
achieve a dual neuroprotective effect91; glutamergic toxicity is combated with NR1 
antibody, and oxidative injury is addressed with superoxide dismutase. Protein modified 
PBCA-NPs were cultured with neurons and cellular uptake was tracked through confocal 
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microscopy. Neuroprotective efficacy was monitored via superoxide challenge and live/dead 
assay. PBCA-NPs were taken up by neurons, and no dead neurons were found in treated 
cultures, with or without superoxide challenge. No live cells were found in the untreated, 
challenged cells. This study is preliminary, and more work, particularly animal studies, will 
need to be done to assess the full potential of this treatment.
Another interesting NP under evaluation for its neuroprotective properties is auto-catalytic 
nano-ceria particles.92 These ceria NPs have the ability to harvest reactive oxygen species 
and undergo catalytic oxidative recovery, refreshing themselves. Neuroprotection and 
general biocompatibility were gauged in an in vitro adult rat nerve model. Ceria NPs were 
incubated with neural cells harvested from enzymatically digested adult rat spinal cords and 
were assessed in a hydrogen peroxide injury model by culture assays, UV-vis spectroscopy, 
and patch clamping. Compared with controls, cells treated with ceria NPs had significantly 
more live cells, fewer dead cells, and more neurons after the challenge. They were also able 
to demonstrate voltage dependent inward and outward currents, and to generate single action 
potentials. UV shift results demonstrate that the NPs have the capacity for catalytic 
oxidative recovery, which indicates that they have a pseudo-infinite half-life for antioxidant 
activity. To assess treatment possibilities, more studies need to be performed on these 
particles. These studies may include bioavailability, targeting, toxicity, and in vivo 
functional recovery tests.
3.4 Liposomes
Liposomes have long been a popular subset of nanoscale drug carriers. Liposomes are easy 
to prepare, biocompatible, non-toxic, and hydrophilic drug can be easily loaded into the 
aqueous inner core.93 Multifunctional transactivating-transduction protein and PEG 
modified magnetic polymeric liposomes (TAT-PEG-MPLs) were tested for their 
bioavailability and delivery capabilities in an in vivo rat SCI model.94, 95 These liposomes 
possess several interesting characteristics. As the liposomes have an iron core, they can be 
used as a contrast agent for MRI. Additionally, conjugation with transactivatingtransduction 
protein, which is derived from HIV and can penetrate cell membranes, facilitates transfer 
across the BSCB.19, 96 PEG is effective in both targeting damaged areas in the cord and 
sealing damaged membranes.77 In this study, no drug was loaded into the TAT-PEG-MPLs. 
Subsequently, functional recovery and neuroprotection were not evaluated and the focus was 
on the efficacy of delivery. Rats suffering impact injury to the spinal cord were dosed with 
TAT-PEG-MPLs, which were injected into the caudal vein. Animals were sacrificed 72 
hours later. Accumulation of iron at the lesion site was evaluated via staining, MRI, electron 
microscopy, and flame atomic absorption spectrophotometry. A low signal was observed 
from T2-weighted MRI images. Flame absorption spectrophotometry demonstrated that 
significantly more iron accumulated around the lesion site, indicating successful delivery of 
the liposome payload. The data suggests that this delivery system is effective in crossing the 
BSCB and delivering a payload preferentially to the damaged spinal cord. As delivery is 
effective, it would be interesting to see results of animal testing that evaluates recovery. 
Although this delivery system seems to be effective, liposomes do have some limitations. 
Liposomes can be quickly removed from the system by the reticuloendothelial system. A 
second limitation is that liposomes, like micelles, have also been known to destabilize and 
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drop their payload in the blood due to interactions with plasma proteins.97 Careful design of 
the liposome with attention to the size, lipid content, or surface of the liposome can help 
somewhat to mitigate these problems.98
3.5 Carbon-based nanomaterials
In addition to the previously discussed carriers, carbon-based nanomaterials have been 
explored for applications in neuroprotection. Both carbon nanotubes and fullerenes have 
been explored for SCI treatment. Fullerenes are three-dimensional molecules completely 
composed of carbon and offer several benefits for neuroprotection; fullerenes can scavenge 
more than one free-radical per molecule, they have active sites for easy functionalization, 
and they also have structural and chemical flexibility.99, 100 Although insolubility in water 
has been limiting in the past, several different fullerene derivatives have been developed that 
are soluble.101, 102 Carboxyfullerenes, C60, have demonstrated potent free-radical 
scavenging properties and neuroprotective effects against two forms of apoptosis through 
reduction of hyrdoxy radical and superoxide radical concentrations.103 Several studies with 
implications in SCI have been performed to better characterize the neuroprotective potential 
of fullerenes. In one study, C60 derivative fullerenols were shown to be effective neuro-
protectors by blocking glutamate pathways and reducing intracellular Ca2+.104 Another 
study demonstrated that covalently bonded C60- ebselen derivatives were more effective 
than C60 alone, ebselen alone, and a combination of the two agents in preventing cell injury 
in an H2O2 challenge model of cell injury.105 While fullerenes have interesting 
neuroprotective effects, to our knowledge they have not yet been applied to an in vivo model 
of SCI.
Carbon nanotubes are another carbon-based nanomaterial that has been applied to SCI 
treatment. Carbon nanotubes are electrically conductive, and also have a similar size scale to 
neuronal processes. They are also flexible, strong, durable, and easy to modify. Testing has 
also shown that carbon nanotubes can promote outgrowth of neurites in cell 
culture.106, 107, 108 Roman et al tested single-walled carbon nanotubes functionalized with 
PEG (SWNT-PEG) in vivo in a rat transection model of SCI.109 Animals were either treated 
with 25uL of a saline control or SWNT-PEG (1ug/mL, 10ug/mL, or 100ug/mL), injected 
into the lesion epicenter one week after the spinal cord transection. Functional recovery of 
the animals was assessed by behavioral analysis, and immunohistochemistry was used to 
detect lesion volume, glial scarring, and axonal morphology. The authors found that the 
SWNT-PEG treatment modestly improved locomotor recovery; animals receiving 
100ug/mL SWNT-PEG had statistically significant recovery compared to the control group 
by 35 days post-injury, scoring approximately 3 as compared to approximately 0.5. This 
means that treated animals had spontaneous extensive movement of two joints, and control 
animals had either no observable joint movement or only slight movement of one or two 
joints.66 Animals receiving SWNT-PEG treatment were observed to have decreased lesion 
volume and increased neurofilament-positive fibers and corticospinal tract fibers in the 
lesion. Higher doses of SWNT-PEG contributed to more significant results. Although the 
carbon nanotubes are not biodegradable, it did not appear that they increased reactive gliosis 
or caused toxicity. The authors did not look deeply into the mechanisms behind the repair, 
but pondered that the observed recovery could be the result of either carbon nanotubes 
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promoting outgrowth by direct contact with neurons, or, citing Shi et al and their study of 
PSiNPs, protective effects from bound PEG interacting with damaged cell membranes. It is 
important to note that the complete transection model induces a sizable lesion and therefore 
contributions from spared tissue towards recovery are extremely limited. For this reason, 
recovery in all groups was much lower. Additionally, treatment was given very late 
following injury, spanning the injury phase between secondary injury and chronic injury. 
This may contribute to the modest nature of the results. Because the treatment was given one 
week post-injury and since the mechanisms of repair may be due to either protective or 
regenerative effects, some may choose to characterize this treatment as regenerative rather 
than neuroprotective. Due to the formulation, delivery, and application of PEG in the 
treatment, we have chosen to include it in the neuroprotective section.
To summarize, effects of secondary injury can be mitigated through neuroprotective 
treatment, and nanomedicine shows a great potential for targeting and treating various 
causes of damage. The human spinal cord provides a unique and challenging environment 
for drug delivery, but with clever design these obstacles and barriers can be maneuvered. 
Well-designed carriers can be used to prolong circulation or cross the BSCB to improve 
bioavailability of drug to the spinal cord. It is important to understand the limitations of NPs 
and carriers. As discussed earlier, micelles and liposomes can be unstable in the blood and 
drop their payload soon after injection.67,68,97 This limitation is necessitating the 
development of alternative carrier designs. Nanocarriers and nanoparticles must also 
contend with clearance or cellular uptake related to size, shape, surface charge, and 
flexibility.110-112 Careful attention pertaining to these factors during design and surface 
modification can help to mitigate these issues.
Because an understanding of toxicity, delivery, targeting, specificity, and efficacy is crucial 
for any drug, a great need still exists for in vivo testing to investigate the neuroprotective 
capacity of newer treatments. A major challenge in this area is comparing treatment results. 
Comparison of treatments across laboratories is difficult; many different injury models, 
treatment schedules, dosing schemes, and analysis methods are used to study SCI. Because 
of these differences, it is very challenging to ascertain which treatment may provide the best 
results. For example, prognosis following a contusion injury and a transection injury are 
very different, and subsequently, recovery looks different for these models. Treatment given 
at different post-injury time points will have different effects; it may be more effective when 
given at a certain time post-injury (e.g., within 8 hours). At this early investigative stage, 
most studies apply the drug at only one time point post-injury, in one dosing scheme, and in 
one animal injury model; a limitation which perhaps confounds effects. Since it is not 
possible to test all viable methods, results must be analyzed critically.
Great progress has been made in identifying and developing nanomedicine with the capacity 
to mitigate harm caused by SCI, but there is still a great need to repair the remaining damage 
that could not be avoided and rebuild the disrupted neural networks. Chronic injury is 
another issue that can only be addressed through regrowth of neural networks. For those 
suffering from paralysis related to SCI it is already too late to allay damage. To re-knit 
spinal tissue and awaken new growth we must rely on regeneration techniques.
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4. Nanomaterials for Neural Regeneration
Regeneration of the CNS is much more difficult than that of the peripheral nervous system 
(PNS), which is capable of spontaneous regeneration. In the PNS, damaged axons can 
overcome large gaps to reconnect and promote recovery with help from guidance tubes and 
nerve grafts.113, 114 In PNS injury, axons at the distal end degenerate and axons at the 
proximal end elongate, develop growth cones and can reconnect, forming synapses to nerves 
or muscles. Schwann cells assist in the process by remyelinating axons and by producing 
growth factors and an extracellular matrix (ECM) that guide axon growth.115 Regeneration 
of the CNS is more difficult for several reasons. In the CNS, oligodendrocytes that 
myelinate the axons make up a much smaller proportion of the cells than Schwann cells do 
in the PNS. When oligodendrocytes are damaged or die, a greater number of axons are 
affected by the loss, reducing support for regeneration. Degraded myelin poses another 
complication; it contains growth inhibitors that are cleared slowly in the CNS.116 
Furthermore, cyst and glial scar formation are significant physical and chemical barriers to 
regeneration.117 Although these hurdles to regeneration are disheartening, only a small 
number of tracts need to be preserved or regenerated in order to maintain function.118
A significant goal in neural regeneration is to provide an environment that is permissive to 
axon growth. This can be done by promoting neurotrophic factors, blocking inhibitory 
factors, and through pharmacological intervention or cell introduction.48 To bridge a 
physiological gap in tissue caused by lesion formation or to prevent a lesion from forming, a 
scaffold can be incorporated into the damaged portion of the spinal cord. This can be done 
either through surgical implantation, or in the case of self-assembling scaffold and 
hydrogels, through injection.
Scaffolds provide structural support for the damaged spinal cord and also a physical surface 
for regeneration, guiding and supporting cell growth from migration or transplantation. 
Several different nanomaterial approaches to scaffolding have been explored: nanofiber 
scaffolds, self-assembled peptide systems, and nanofiber conduits. Regenerative methods 
can be combined with drug or cell therapy for a combinatorial approach. A summary of the 
regenerative approaches discussed in this manuscript can be found in Table 2. For all 
regeneration techniques, environmental cues are very important to ensure that cells 
differentiate and develop in physiologically relevant ways. For this reason, it is desirable 
that the mechanical and chemical properties of the regenerative scaffold closely match those 
of the native tissue.119, 120 Nanomaterial scaffolds can be modified to resemble the ECM or 
promote regeneration through various surface attachments of peptides.121 Through surface 
attachment, scaffolds can promote neurite outgrowth, mediate cell adhesion, or promote cell 
spreading.122, 123 Environmental cues have been widely explored in preliminary testing and 
applications of electrospun nanofiber scaffolds.
4.1 Electrospun nanofiber scaffolds
In one experimental example of surface functionalization, Ahmed et al attached neurite 
outgrowth promoting tenascin-C-derived peptides to electrospun polyamide nanofiber 
scaffolds. They demonstrated that neural cells cultured on the functionalized scaffold had 
significantly more neurites, more neuronal attachments, and greater neurite extension.124 
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Similarly, it was determined by Koh et al that incorporation of the ECM protein laminin 
improved the neurite growth and extension of PC-12 cells on a poly(L-lactic acid) nanofiber 
scaffold.121
Orientation of nanofibers within a scaffold can also significantly affect the regeneration 
process. Xie et al studied the differentiation of embryonic stem cells seeded on both 
isotropic and anisotropic biodegradable poly(ε-caprolactone) (PCL) nanofiber scaffolds 
prepared via electrospinning. They discovered that scaffolds with aligned fibers not only 
discouraged the differentiation of embryonic stem cells into astrocytes, which are prevalent 
in glial scarring; but also promoted outgrowth of neurites parallel to the direction of fiber 
alignment.125 Looking into this phenomenon further, they found that dorsal root ganglia 
cells grown on the border between random and aligned fibers grew simultaneously radially 
and directionally, depending on the underlying fiber orientation.126 In the same study, dorsal 
root ganglia cells were grown on double layer scaffolds in which fibers were aligned in 
different directions. This resulted in a biaxial growth pattern, which suggests that different 
layers of the scaffold can influence neurite outgrowth. Meiners et al reached a supporting 
conclusion regarding neurite outgrowth during an in vivo experiment in which polyamide 
nanofiber fabric was implanted into a rat hemi-section model. Although axonal growth was 
supported, the random orientation of the fibers in the fabric impeded the forward movement 
of the neurites and subsequently, regeneration was not very successful.127
4.2 Conduits
Another option for directing neuronal growth is the use of conduits. Conduits are tubes that 
facilitate communication between the proximal and distal ends of the nerve gap and provide 
physical guidance for regrowth. Conduits have been successful in peripheral nerve 
regeneration, as demonstrated by feats like the regeneration of sciatic nerve over an 80mm 
gap in a beagle model using a polyglycolic acid-collagen tube filled with laminin coated 
collagen fibers.128 Nanofibrous conduits can be formed via electrospinning and have been 
used for peripheral nerve regeneration. In one recent study, PCL nanofibrous conduits were 
able to close a 15mm gap in a rat sciatic nerve model and were also able to generate 
significantly more myelinated axons with thicker myelin sheaths than microfiber conduits 
and film conduits.129 Clearly, nanofibers have significant benefits in neural regeneration. 
However, despite the success of collagen and nanofibrous conduits in peripheral nerve 
regeneration, nanoscale conduits have been less successful in repairing SCI. In one study by 
Liu et al, tubular conduits were formed from either random or aligned electrospun collagen 
nanofibers and implanted in a short-term rat hemisection model of SCI.130 Regardless of 
fiber orientation, neurofilament sprouting was observed at 10 days post-implantation, 
although the orientation of these regenerated axons was not obvious. There were a limited 
number of neural fibers observed in the center of the conduit, even at 30 days post-
implantation. Further improvements on these nanofibrous conduit systems can be made 
through surface functionalization, and perhaps future designs will be more successful. 
Although these electrospun scaffolds and conduits have the orientation benefits of aligned 
fibers and directional guidance, a limitation of these systems is that they must be invasively 
implanted into the subject. This can cause further damage to the spinal cord by disrupting 
spared tissue, and lead to infection or other surgical complications.131 To overcome these 
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limitations associated with implantation there has been increasing interest in injectables, 
such as self-assembling scaffolds and hydrogels, which solidify under in vivo conditions.
4.3 Self-assembling systems
Self-assembling peptide systems are synthetic amino acid based systems that transition from 
a solution to a gel within seconds under in vivo pH and ion concentration conditions. The 
resulting material is a nanofibrous mesh similar to the native ECM that biodegrades 
naturally several weeks after implantation.132 The gels are generally biocompatible and non-
cytotoxic, although in some cases pH must be buffered prior to implantation. The gels can 
also safely encapsulate cells or drugs for combination therapies.133 Self-assembling peptide 
systems are generally divided into several categories; self-assembling peptide amphiphiles 
(PAs), self-assembling peptide nanofiber scaffolds (SAPNSs), Amphiphilic diblock 
copolypeptide hydrogels (DCHs), and mixing induced two component protein gels 
(MITCHs).134 DCHs are synthetic polymers, which, through hydrophobic association in 
water, form into gel structures with porous fibril-like nanostructures. DCHs have been 
successfully injected without significant immune response or toxicity into the mouse 
forebrain, and were able to integrate with tissue, support the in-growth of blood vessels, glia, 
and some nerve fibers.135 MITCHS are synthetic protein gels and can be formed to gel upon 
the mixing of its two protein components. MITCHs have been shown to support neural stem 
cells, which were able differentiate, replicate, and sprout neurites. 136 Neither DCHs nor 
MITCHs have been successfully applied yet in an in vivo SCI model.
SAPNSs have been used in several in vivo models with promising results. SAPNSs are 
synthetic biomaterials formed of ionic self-complementary peptides that form into a 
nanofilimentous, hydrated scaffold under in vivo pH. Guo et al used RADA16-1 SAPNS 
loaded with either Schwann cells or neural progenitor cells in an in vivo rat transection 
model of SCI.133 Because of the low pH when untreated, the SAPNSs were neutralized 
before transplantation; otherwise the treatment damaged the host tissue. When evaluated 
after 6 weeks the neutralized SAPNSs had integrated well with the host tissue and had 
greatly decreased inflammation at the lesion site. SAPNSs seeded with cells, especially 
Schwann cells, showed many axons infiltrating the implant. Furthermore, host cells had 
migrated into the implant and there was robust growth of blood vessels, indicating the 
potential for repairing damaged tissue and providing the necessary supporting vasculature.
A similar study was performed by Cigognini et al using RADA16-1 SAPNSs modified with 
bone marrow homing motif (BMHP1), which has previously demonstrated the ability to 
promote nerve tissue regrowth, and a linker (4G).137, 138 In an in vivo rat contusion model, 
RADA16-1-4G-BMHP1 was injected immediately following injury. Assessment of gene 
expression at 7 days demonstrated that in treated animals there was a general upregulation of 
GAP-43, which correlates with axonal regeneration139; trophic factors, which suggests 
synaptic formation140; and ECM remodeling proteins, indicating restructuring of the ECM 
and subsequent axonal growth141. Together, these results suggest tissue regeneration. BBB 
scoring was performed for 8 weeks to track locomotor recovery, and it was found that there 
was a very small but statistically significant improvement in motor performance and 
coordination. Additionally, the SAPNS was compatible with surrounding nervous tissue and 
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was able to fill the cavity. Within the lesion there was increased cellular infiltration, 
basement membrane deposition, and axon regeneration and sprouting. This study confirms 
the potential uses of SAPNSs as a less invasive means of treating SCI.
Self-assembling PAs have also been successfully tested in vitro andin vivo. PA molecules 
assemble into supramolecular nanofibers, which at in vivo ion concentration form a 
continuous, random, mesh-like network. In one study by Tysselin-Mattiace et al PAs were 
designed to display the laminin epitope IKVAV upon assembly.132 The IKVAV epitope is 
known to promote outgrowth of neurites and suppress formation of astrocytes, two 
properties that are desirable for preventing glial scarring.142 In this study, IKVAV PAs were 
injected into a compression injured mouse model of SCI 24 hours post-injury. Several 
different beneficial effects were observed with this treatment. IKVAV PAs successfully 
reduced astrogliosis and cell death. At 11 weeks post-injury it was observed that almost 80% 
of all labeled motor axons in the IKVAV PA group entered the lesion compared with 50% in 
the control group. Furthermore, while no fibers in the control group made it even a quarter 
of the way across the lesion, 50% of the fibers in the treated group penetrated half way 
through, and 35% traversed the entire lesion. Similar results were found with the sensory 
axons at 11 weeks, as 60% of axons entered the injury site in the IKVAV PA group, and 
only 20% did in the control group. Of these axons, none in the control group penetrated 
halfway, while 25% of the fibers in the treated group made it half the way across the lesion 
and 10% crossed the whole gap. Although these axons took indirect routes through the 
lesion, indicating a lack of directional cues, crossing the injury site is a very noteworthy 
accomplishment. A small but statistically significant behavioral improvement was also 
observed using a modified BBB scoring system. The IKVAV PAs demonstrated a good 
starting point for noninvasively repairing SCI within a clinically relevant treatment window.
4.4 Combination of self-assembling and scaffolding systems
In order to glean the benefits of both self-assembling systems and directional cues provided 
by scaffolding, combination approaches have been developed. Gelain et al developed 
composite guidance channels constructed from electrospun PLGA/PCL nanofibers filled 
with RADA16-1-BMHP1 self-assembling peptides in order to tackle the substantial 
challenge of chronic SCI.143 This “neuro-prosthesis” was implanted at the injury site 1 
month after contusion injury in a rat model, and was evaluated 6 months later. At the time of 
evaluation, while cysts persisted in control and sham animals, there was neo-formed tissue 
in the animals receiving the microconduit implants. This neo-tissue lacked inflammation and 
contained regenerating axons and myelin, well-developed vascular structures, cellcell-
deposited ECM, and stromal cells. An example of these results can be seen in Figure 3.143 
Furthermore, there was a significant improvement in the motor function of the animals as 
evaluated by BBB scoring, and also in evoked responses in the ascending tracts. This strong 
evidence demonstrates that it is possible to reconstruct the anatomical and histological 
framework and restore significant motor and electrical function in a chronically injured 
spinal cord. Despite the successes observed, this method does not solve the problem of 
invasive surgery and many complications were observed; 25-33% of animals died due to 
postsurgical complications. However, it still is an incredible step in treating chronic injury, 
which so many patients currently suffer from.
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4.5 Combination of nanofiber scaffolding and electrical stimulation
Another interesting combination method under investigation for regenerating the spinal cord 
is the combination of nanofiber scaffolding and electrical stimulation. Electrical stimulation 
has long been investigated and used in treatment of SCI.36, 37, 144, 145 It is known that in the 
absence of topographical cues neurons align and extend in the presence of electrical 
stimulation.146, 147 Electrically conductive synthetic polymers, such as polypyrrol (PPy) or 
polyaniline, have been combined with biodegradable polymers and investigated as 
scaffolding materials for repairing conducting tissue. These polymers have even been used 
for in vivo testing as an interior coating on conduits for nerve repair.148-150 In one study, a 
nanofibrous mesh-like electrospun PLGA scaffold coated with a nanothick layer of PPy was 
tested for potential application as neural scaffold material.151 Neurons were cultured on both 
aligned and random scaffolds, and electrical stimulation was applied to the cells. It was 
found that in the presence of stimulation 40-90% more neurites were generated and neurites 
were 40-50% longer. Furthermore, there were more and longer neurites on the aligned 
scaffolds than on the random scaffolds, suggesting combined benefits. Conductive-core 
sheath PCL-PPy and poly(L-lactide)-PPy (PLA-PPy) nanofibers have found similar success. 
In a study by Xie et al, it was found that dorsal root ganglion cells incubated with uniaxially 
aligned core-sheath PLA-PPy and PCL-PPy nanofiber scaffolds had a 1.82-fold increase in 
neurite extension compared with randomly aligned scaffolds.152 With electrical stimulation 
there was an increase in neurite length of 1.83-fold and 1.47-fold for aligned and random 
scaffolds respectively, again demonstrating the synergistic effects of electrical stimulation 
and fiber alignment. Carbon nanostructures also have the ability to conduct electricity. As 
detailed earlier, carbon nanotubes have been tested previously for a neuroprotective and 
regenerative SCI treatment109 and also have been investigated for regenerative nerve 
repair.107, 153-155 Carbon nanotubes have also been applied in multifunctional neural 
interfaces that provide electrical and topographical cues.156 Given their unique properties, 
carbon nanotubes provide a wealth of options, including functionalization, incorporation 
into scaffolding, and electrical stimulation; all of which are interesting and promising 
directions for regenerative treatment.
Although testing has been limited to in vivo testing so far, electrically stimulated 
nanoscaffolding is an intriguing option for spinal cord repair and regeneration, although in 
vivo integration of stimulation in a safe and effective manner may prove to be a substantial 
challenge.
5. Discussion
Although SCI will never disappear entirely, perhaps future victims of SCI will not share 
quite the same fate as those who suffer today. Treatment of both acute and chronic SCI 
injury remains a multi-faceted medical challenge, but with continued investigations of 
nanomedicine, the future looks bright. There has been general consensus157-159 that in order 
to achieve the best effects a combination of both neuroprotection and regeneration 
treatments should be employed. This dual pronged approach would work to decrease the 
amount of regeneration necessary by sparing the maximum amount of tissue, then work to 
repair this latent damage, resulting in a maximally healed and functional spinal cord. As 
Tyler et al. Page 16
Nanoscale. Author manuscript; available in PMC 2015 March 25.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
both fields continue to advance, a combined approach could help us realize the goal of 
functional recovery much faster than either field could on its own. NPs,75, 76 liposomes,94, 95 
and micelles59 have shown the ability to increase bioavailability of neuroprotective therapies 
to the spinal cord after injection. Such improvements in delivery have the capability of 
improving clinical outcomes by reducing the required dosages and systemic toxicity of 
current treatments. These delivery vehicles also have the flexibility to potentially deliver 
other drugs that may improve upon current standards. Besides improving the bioavailability 
of neuroprotective treatment, nanomaterials with innate neuroprotective attributes, such as 
mPEG-PDLLA micelles,60 ceria NPs,92 fullerenes,104, 105 and carbon nanotubes,109 have 
been developed and tested in vivo or in vitro with varying degrees of success. While in vitro 
testing can give an indication of the abilities of the nanomaterial, in vivo testing is very 
important for establishing clinical value. Neuroprotective treatments like mPEG-PDLLA 
micelles,60 PSiNPs,75, 76 and MP-NPs,71 have had successful in vivo tests, and demonstrate 
exciting and significant behavioral or electrical functional recovery. Treatments, such as 
SWNT-PEG,109 temperature responsive pluronic NPs,72 and TAT-PEG-MPLs94, 95 have 
been tested in vivo, but may consider changing the focus of the study (e.g., from delivery or 
characterization to recovery) or using alternative animal models (e.g., contusion instead of 
complete transection) that would permit a better comparison with other treatments. Still 
other treatments, such as ceria NPs92 and PBCA-NPs,91 are intriguing prospects but have 
not been tested in vivo will require a great deal of validation.
Neural regenerative strategies have also had success with nanomedicine, specifically 
nanostructures. Nanofiber scaffolds, self-assembling systems, conduits, and combination 
systems have demonstrated promising results in both and in vivo and in vitro testing. Self-
assembling peptides132, 133, 137, 138 were able to show formation of blood vessels, significant 
progression of motor fibers through the lesion site, recovery of function and a significant 
reduction in astrocytes production. These results are promising steps towards developing full 
vascular support, eliminating glial scar formation, and recovering conduction; important 
building blocks towards full recovery. Successful repair of chronic injury is especially of 
notice, particularly because there are so many patients currently suffering from paralysis. 
The combination microchannel guidance and self-assembling peptide scaffolding 
neuroprosthetic implant143 showed exciting results in treating chronic SCI. While this 
device was able to successfully develop neo-tissue and have functional motor and electrical 
recovery, there were many problems related to the invasive application of the device that 
must be resolved before possible application in humans. If results like these can be achieved 
in a chronic case with non-invasive techniques, the implications would be enormous. 
Although there is a great deal of work to be done in this area, especially with successful 
integration of directional, chemical, and structural cues in a non-invasive manner, a great 
deal of progress has been realized in a few short years and this advancement will only 
continue with development and application of new nanotechnologies.
For both regenerative and neuroprotective strategies, comparative studies between 
treatments involving several different markers for functional recovery may be an important 
next step in identifying treatments to move forward with for further development and 
clinical testing. The best treatment may not yet have been developed, but some the current 
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research examined has shown significant improvement over the current standards of care. 
With the progression of nanomedicine, we are entering a new stage in the evolution of SCI 
treatment. Although there are still many obstacles ahead of us, the future is bright. 
Nanomedicine, with its multifunctional and combinatorial capabilities can allow these 
treatment approaches to be blended, providing avenues through which the dream of 
preventing or reversing paralysis caused by SCI may be attained.
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Figure 1. 
Pathophysiology of spinal cord injury, demonstrating pathological events during primary 
SCI, secondary SCI, and recovery phases. Mechanical trauma leads to disruption in blood 
flow, hemorrhage, ischemia, hypoxia, membrane damage, edema, glutamate release, and 
inflammation. These are often followed by glutamate mediated cytotoxicity, calcium 
mediated injury, lipid peroxidation, electrolyte imbalance and apoptosis. Dysfunction during 
recovery resulting from injuries occurs because of neuron loss and an environment that 
inhibits regeneration.
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Figure 2. 
Neuroprotection from mPEG-PDLLA micelles. Calcium influx into axons. (a-c) TPEF 
images of OG 488 (green) and coherent anti-Stokes Raman scattering images of myelin 
(red) show intra-axonal free Ca2+ levels in compression-injured (a), healthy (b), and 
compression-injured and micelle-treated (c) spinal cords. Images were acquired 1h after 
compression injury. (d) Statistical analysis. Without micelle treatment, the TPEF intensity 
from OG inside the injured axons was 10 times greater than intact axons. The intensity was 
only twice that of intact axons when 0.67 mg/ml micelles were added immediately after 
compression injury.
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Figure 3. 
Nerve regeneration in chronically injured rat spinal cord using PLGA/PCL microchannel 
conduits with RADA16-1-BMHP. Dashed lines outline implanted channel walls in (A-C). In 
transverse sections (A), GAP-43 positive fibers were found inside and between transplanted 
tubes (arrows; coronal section). (B) NF200 positive fivers were seen crossing the top rostral 
interface of the lesion. (C) βIII-tubulin positive fasciculi stretched through the lumen of the 
conduits in a longitudinal spinal cord section. (D) Quantitative analysis (mean +- SEM) of 
the percentage of channels showing positivity for neural markers throughout the entire tube 
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length (N=5 for group 1, N-8 for group 8). Statistical significance (*) p=0.03; (**) p = 
0.003. NF200 (green) and GAP43 (red) did not colocalize inside the same fiver (E). 
Myelinated (green, arrow) and unmyelinated (red, arrowhead) βIII-tubulin positive fibers (F) 
were observed (enlargement in G). Both SMI-32 (H) and SMI-31 (I) positive fibers were 
detected within guidance conduits, in adjacent coronal sections. In the longitudinal 
reconstruction of transplanted cord in (J) (group 2), NF200 positive fibers cover the whole 
length (approx 2 mm) of the lesion, crossing both the rostral and the caudal channels/tissue 
interfaces (dotted line).
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Table 1
Nanomedicine for Neuroprotection
Model Methods Mechanism
Nanowires
TiO2 Acure47,48
Sharma et al
In vivo - rat
■ Dorsal horn incision
Permeability, edema, pathology, motor 
recovery - 5 hours
Improve compound delivery
Micelles
PEO-PPO-PEO MP50
Chen et al
In vivo - rabbit, mice
■ Crush
Release characteristics, bioavailability, 
anti-apoptotic protein and mRNA levels - 
24 hours
Improve MP delivery
mPEG-PDLLA51
Shi et al
Ex vivo - rat spinal cord
■ Crush
In vivo - rat
■ Crush
Ex vivo: CAP, myelin imaging
In vivo: BBB, toxicity analysis, Ca2+ 
influx, lesion volume, immune reactivity 
- 4 weeks
Seal cell membranes
Nanoparticles
MP-NPs59
Kim et al
In vivo - rat
■ Dorsal hemisection
Protein expression - 24h Cellular 
reactivity, lesion volume, functional 
recovery - 2&4 weeks
Improve MP delivery
PEO-PPO-PEO 
magnetic NPs60
Chen et al
In vivo - rat
■ Transection
Immunohistochemistry, toxicity via body 
weight and mortality - 4 weeks
Improve delivery of GM-1
PSiNPs63,64
Cho et al
Ex vivo - guinea pig spinal 
cord
■ Transection
In vivo - guinea pig
■ Crush
Ex vivo: LDH, ROS, LPO assays, CAP, 
TMR fluorescence
In vivo: SSEP - 24h, 1 & 2 weeks
Seal cell membranes
MSN-hy-PEG72
Cho et al
In vitro - PC12
■ Acrolein challenge
LDH, MTT, ATP, and glutathione assays Seal membrane, scavenge 
acrolein
SOD-NR1-PBCA NPs79
Reukov et al
In vitro - cerebellar neuronal 
cells
■ Superoxide xanthine/
xanthine oxidase challenge
Fluorescent microscopy, Live/Dead assay Protect from glutamergic 
toxicity, scavenge ROS
Ceria NPs80
Das et al
In vitro - adult rat spinal cord 
cell culture
■ H2O2 challenge
Live/Dead assay, patch clamping Scavenge ROS
Liposomes
PEG-TAT-MPLs82,83
Liu et al
Wang et al
In vivo - rat
■ Contusion
MRI, staining, electron microscopy, 
flame atomic absorption spectroscopy - 
72h
Improve delivery and 
bioavailability
Fullerenes
C60(OH)n90
Jin et al
In vitro - neuronal cells
■ Glutamate and H2O2/Fe2+ 
challenges
LDH, GABA, and Taurine assays, Ca2+ 
influx, morphology
Block glutamate receptors, 
lowering intracellular Ca2+
C60-ebselen91
Liu et al
In vitro - cortical neuronal 
cells
■ H2O2 challenge
LDH and MTT assays Scavenge ROS
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Table 2
Nanomedicine for Neuro-regeneration 1
Model Methods Mechanism
Electrospun scaffolds
Polyamide w/ Tenascin C 
peptide103
Ahmed et al
In vitro - Neural Neurite outgrowth quantification Promote outgrowth
PLLA w/laminin100
Koh et al
In vitro - PC-12 Neurite outgrowth quantification Promote attachment
PCL isotropic & 
anisotropic104
Xie et al
In vitro -ESCs Neurite outgrowth quantification, 
differentiation
Directional cues
PCL isotropic and 
anisotropic & orthogonal 
layers105
Xie et al
In vitro - DRGs Neurite outgrowth quantification Directional cues
Polyamide - Tenascin C 
fabric106
Mieners et al
In vivo - rat
■ Hemisection
Neurite outgrowth quantification-3 & 5 weeks Promote outgrowth
Conduits
Collagen nanofibrous 
conduits109
Liu et al
In vitro - DRGs
In vivo - rat
■ Hemisection
In vitro: Immunostaining
In vivo: Immunostaining, neurite outgrowth 
and axon formation quantification, cell 
infiltration -10 & 30 days
Directional cues
Self-Assembling Structures
RADA16-1 SAPNSs w/SCs or 
NPCs112
Guo et al
In vivo - rat
■ Transection
Staining, axon quantification, lesion volume - 
6 weeks
Mimic ECM Neural 
implantation
RADA16-1 -4G-BMHP1 
SAPNSs117
Cigognini et al
In vivo - rat
■ Contusion
Gene expression - 3&7 days
Lesion volume, staining, histology, BBB 
scoring - 8 weeks
Mimic ECM
Promote tissue growth
IKVAV PAs111
Tysselin-Mattiace et al
In vivo - mouse
■ Compression
Axonal outgrowth quantification - 24h & 9 
weeks
Modified BBB - 9 weeks
Mimic ECM
Promote outgrowth
Suppress astrocytes
Combination Self-Assembling and Scaffolding
PLGA/PCL microchannel 
conduits w/RADA16-1-
BMHP122
Gelain et al
In vivo - rat
■ Contusion (chronic)
Evoked potentials, BBB scoring, Immune 
response, staining- 24 weeks
Mimic ECM
Directional cues
Promote tissue growth
Conducting Scaffolds
PLGA-PPy scaffold Aligned/
random130
Lee et al
In vitro w/electrical 
stimulation
Neurite outgrowth quantification Directional cues
Electrical cues
Conductive-core sheath PCL-
PLA-PPy131
Xie et al
In vitro w/electrical 
stimulation
Neurite outgrowth quantification Directional cues
Electrical cues
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